- Home
- XAIR vs ALLR Comparison
XAIR vs ALLR Comparison
Compare XAIR & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XAIR
- ALLR
- Stock Information
- Founded
- XAIR 2011
- ALLR 2004
- Country
- XAIR United States
- ALLR United States
- Employees
- XAIR N/A
- ALLR N/A
- Industry
- XAIR Medical/Dental Instruments
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- XAIR Health Care
- ALLR Health Care
- Exchange
- XAIR Nasdaq
- ALLR Nasdaq
- Market Cap
- XAIR 17.0M
- ALLR 15.8M
- IPO Year
- XAIR N/A
- ALLR N/A
- Fundamental
- Price
- XAIR $2.43
- ALLR $1.66
- Analyst Decision
- XAIR Strong Buy
- ALLR Strong Buy
- Analyst Count
- XAIR 1
- ALLR 1
- Target Price
- XAIR $11.00
- ALLR $9.00
- AVG Volume (30 Days)
- XAIR 8.8M
- ALLR 21.5M
- Earning Date
- XAIR 11-10-2025
- ALLR 08-15-2025
- Dividend Yield
- XAIR N/A
- ALLR N/A
- EPS Growth
- XAIR N/A
- ALLR N/A
- EPS
- XAIR N/A
- ALLR N/A
- Revenue
- XAIR $4,782,000.00
- ALLR N/A
- Revenue This Year
- XAIR $265.24
- ALLR N/A
- Revenue Next Year
- XAIR $136.17
- ALLR N/A
- P/E Ratio
- XAIR N/A
- ALLR N/A
- Revenue Growth
- XAIR 168.20
- ALLR N/A
- 52 Week Low
- XAIR $2.02
- ALLR $0.61
- 52 Week High
- XAIR $13.52
- ALLR $3.91
- Technical
- Relative Strength Index (RSI)
- XAIR 48.32
- ALLR 59.12
- Support Level
- XAIR $2.13
- ALLR $1.78
- Resistance Level
- XAIR $4.78
- ALLR $1.92
- Average True Range (ATR)
- XAIR 0.32
- ALLR 0.25
- MACD
- XAIR 0.05
- ALLR 0.02
- Stochastic Oscillator
- XAIR 11.82
- ALLR 52.25
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.